BACKGROUND: Balamuthia mandrillaris and Acanthamoeba species are 2 free-living amoebae responsible for granulomatous amoebic encephalitis in humans and animals. We have screened serum samples from hospitalized patients with encephalitis for antibodies against these 2 amoebae as a means of detecting a disease with few defining symptoms and a poor prognosis. METHODS: Indirect immunofluorescence antibody (IFA) staining of serum samples from patients with encephalitis was conducted over a period of 6 years to detect amoeba antibodies. More than 250 serum samples from patients hospitalized with encephalitis were screened. Most of the samples were from patients in California and were screened as part of the California Encephalitis Project, with a small number of specimens from other states. RESULTS: During the course of the study, 7 cases of Balamuthia encephalitis were detected; all cases were detected in Hispanic individuals, and all cases were fatal. Examination of hematoxylin-eosin-stained and immunostained sections of brain tissue obtained at biopsy or autopsy for amoebae confirmed balamuthiasis in all serum samples with positive IFA results. One case of Acanthamoeba encephalitis was detected in an immunocompromised individual with a normal antibody titer by identification of amoebae in immunostained brain tissue obtained at autopsy. CONCLUSIONS: IFA can be successfully used in screening for balamuthiasis and acanthamoebiasis in patients whose clinical presentation, laboratory results, and neuroimaging findings are suggestive of amoebic encephalitis. Ideally, this can lead to an earlier definitive diagnosis and earlier start of antimicrobial therapy. Without IFA staining, the balamuthiasis cases in our study would have been diagnosed as neurocysticercosis, tumor, tuberculosis, or viral encephalitis or would have been undiagnosed.
BACKGROUND:Balamuthia mandrillaris and Acanthamoeba species are 2 free-living amoebae responsible for granulomatous amoebic encephalitis in humans and animals. We have screened serum samples from hospitalized patients with encephalitis for antibodies against these 2 amoebae as a means of detecting a disease with few defining symptoms and a poor prognosis. METHODS: Indirect immunofluorescence antibody (IFA) staining of serum samples from patients with encephalitis was conducted over a period of 6 years to detect amoeba antibodies. More than 250 serum samples from patients hospitalized with encephalitis were screened. Most of the samples were from patients in California and were screened as part of the California Encephalitis Project, with a small number of specimens from other states. RESULTS: During the course of the study, 7 cases of Balamuthia encephalitis were detected; all cases were detected in Hispanic individuals, and all cases were fatal. Examination of hematoxylin-eosin-stained and immunostained sections of brain tissue obtained at biopsy or autopsy for amoebae confirmed balamuthiasis in all serum samples with positive IFA results. One case of Acanthamoeba encephalitis was detected in an immunocompromised individual with a normal antibody titer by identification of amoebae in immunostained brain tissue obtained at autopsy. CONCLUSIONS: IFA can be successfully used in screening for balamuthiasis and acanthamoebiasis in patients whose clinical presentation, laboratory results, and neuroimaging findings are suggestive of amoebic encephalitis. Ideally, this can lead to an earlier definitive diagnosis and earlier start of antimicrobial therapy. Without IFA staining, the balamuthiasis cases in our study would have been diagnosed as neurocysticercosis, tumor, tuberculosis, or viral encephalitis or would have been undiagnosed.
Authors: J Michael Miller; Matthew J Binnicker; Sheldon Campbell; Karen C Carroll; Kimberle C Chapin; Peter H Gilligan; Mark D Gonzalez; Robert C Jerris; Sue C Kehl; Robin Patel; Bobbi S Pritt; Sandra S Richter; Barbara Robinson-Dunn; Joseph D Schwartzman; James W Snyder; Sam Telford; Elitza S Theel; Richard B Thomson; Melvin P Weinstein; Joseph D Yao Journal: Clin Infect Dis Date: 2018-08-31 Impact factor: 9.079
Authors: Brendan R Jackson; Zuzana Kucerova; Sharon L Roy; Glenda Aguirre; Joli Weiss; Rama Sriram; Jonathan Yoder; Rebecca Foelber; Steven Baty; Gordana Derado; Susan L Stramer; Valerie Winkelman; Govinda S Visvesvara Journal: Parasitol Res Date: 2014-01-24 Impact factor: 2.289
Authors: Marta Tavares; Jose M Correia da Costa; S Stirling Carpenter; L A Santos; Caldas Afonso; Alvaro Aguiar; Josue Pereira; Ana Isabel Cardoso; Frederick L Schuster; Shigeo Yagi; Rama Sriram; Govinda S Visvesvara Journal: J Clin Microbiol Date: 2006-07 Impact factor: 5.948
Authors: Sharon L Roy; Jane T Atkins; Rosemaria Gennuso; Danny Kofos; Rama R Sriram; Thomas P C Dorlo; Teresa Hayes; Yvonne Qvarnstrom; Zuzana Kucerova; B Joseph Guglielmo; Govinda S Visvesvara Journal: Parasitol Res Date: 2015-09-02 Impact factor: 2.289
Authors: Wouter Meersseman; Katrien Lagrou; Raf Sciot; Johan de Jonckheere; Christine Haberler; Julia Walochnik; Willy E Peetermans; Eric van Wijngaerden Journal: Emerg Infect Dis Date: 2007-03 Impact factor: 6.883